




Healthcare Industry News: HSMN NewsFeed
News Release - January 11, 2021
MedSkin Solutions Dr. Suwelack AG Receives FDA 510(k) Clearance for MatriDerm(R) - Its Three-Dimensional Acellular Collagen Elastin Dermal Matrix Portfolio
MedSkin Solutions Dr. Suwelack AG announces receiving FDA 510(k) clearance for its flagship Med Care product portfolio MatriDerm®HAMBURG, Germany, Jan. 11, 2021 -- (Healthcare Sales & Marketing Network) -- MatriDerm® is a single-use three-dimensional acellular dermal matrix composed of bovine collagen fibers and bovine elastin. MatriDerm® is indicated for use in the management of full thickness and partial wounds. The technology is supported by over 150 peer reviewed published articles and currently sold across the world having treated over 300,000 patients worldwide.
"Like we have done across Europe, the Middle East, Asia, and Latin America our focus will be educating and supporting healthcare professionals and our partners as we look to commercialize MatriDerm® in the largest medical device market globally," said Jason Gugliuzza, Vice President Med Care Division.
About MedSkin Solutions Dr. Suwelack
MedSkin Solutions Dr. Suwelack AG is a Germany-based expert in biotech solutions for tissue regeneration and skin health. Our technological core competence is our proprietary Advanced CryoSafe™ Method that allows us to maintain and refine the response of bioactive materials. Our science-based solutions create effective and easy-to-use treatments that deliver added value and serve equally patients and physicians. For our Customers, we develop the most effective, targeted and cost-efficient solutions in Regenerative Medicine, Advanced Wound Care and Professional Skin Care.
Source: MedSkin Solutions
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.